(Q24202713)

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Effect of low-dose oral contraceptives on androgenic markers and acne.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

[Ovarian suppression with Diane 35/50]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

An open study of Triphasil and Diane 50 in the treatment of acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

The evaluation and management of acne: economic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Modelling the remission of individual acne lesions in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

New progestogens in oral contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Hormonal therapy for acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Have Oral Contraceptives Reduced the Prevalence of Acne? A Population-Based Study of Acne vulgaris, Tobacco Smoking and Oral Contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Therapy for acne vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

An epidemiological study of acne in female adults: results of a survey conducted in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Allocation concealment in randomised trials: defending against deciphering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Blinding in randomised trials: hiding who got what.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Differences in the use of combined oral contraceptives amongst women with and without acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

New treatments and therapeutic strategies for acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Commentary: A UK primary care perspective on treating acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

A randomized double blind study of two oral contraceptives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Shorter pill-free interval in combined oral contraceptives decreases follicular development

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Effect of a desogestrel-containing oral contraceptive on the skin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Anti-androgen treatment in women with acne: a controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

1 reference

7 January 2021

An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Effects of benzoyl peroxide on lipogenesis in sebaceous glands using an animal model.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004425.PUB5

7 January 2021